Rep. Lisa C. McClain Buys United Therapeutics Corporation (NASDAQ:UTHR) Stock

Representative Lisa C. McClain (R-Michigan) recently bought shares of United Therapeutics Corporation (NASDAQ:UTHR). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in United Therapeutics stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

United Therapeutics Trading Up 1.0%

Shares of NASDAQ:UTHR traded up $4.54 during trading on Tuesday, hitting $481.74. 154,328 shares of the stock were exchanged, compared to its average volume of 588,834. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $485.32. The company has a market cap of $20.74 billion, a PE ratio of 18.25, a P/E/G ratio of 4.96 and a beta of 0.77. The company has a fifty day moving average price of $441.26 and a two-hundred day moving average price of $357.43.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the firm earned $6.39 EPS. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. UBS Group increased their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company raised their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $464.76, for a total transaction of $5,112,360.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,094,337.56. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at approximately $3,818,382.48. This represents a 72.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 519,935 shares of company stock worth $224,879,377 over the last 90 days. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of UTHR. CWM LLC increased its holdings in United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock valued at $1,492,000 after buying an additional 3,487 shares in the last quarter. AXQ Capital LP boosted its stake in shares of United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after purchasing an additional 3,235 shares during the period. XTX Topco Ltd purchased a new stake in United Therapeutics during the 1st quarter worth approximately $313,000. Allianz Asset Management GmbH grew its stake in United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after purchasing an additional 33,254 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.